Skip to main content
Erschienen in: Wiener klinische Wochenschrift 19-20/2014

01.10.2014 | original article

Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020

verfasst von: Doz. Dr. Willi Oberaigner, Dr. Sabine Geiger-Gritsch

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2014

Einloggen, um Zugang zu erhalten

Summary

Background

Prediction of the number of incident cancer cases is very relevant for health planning purposes and allocation of resources. The shift towards elder age groups in central European populations in the next decades is likely to contribute to an increase in cancer incidence for many cancer sites. In Tyrol, cancer incidence data have been registered on a high level of completeness for more than 20 years. We therefore aimed to compute well-founded predictions of cancer incidence for Tyrol for the year 2020 for all frequent cancer sites and for all cancer sites combined.

Methods

After defining a prediction base range for every cancer site, we extrapolated the age-specific time trends in the prediction base range following a linear model for increasing and a log-linear model for decreasing time trends. The extrapolated time trends were evaluated for the year 2020 applying population figures supplied by Statistics Austria.

Results

Compared with the number of annual incident cases for the year 2009 for all cancer sites combined except non-melanoma skin cancer, we predicted an increase of 235 (15 %) and 362 (21 %) for females and males, respectively. For both sexes, more than 90 % of the increase is attributable to the shift toward older age groups in the next decade. The biggest increase in absolute numbers is seen for females in breast cancer (92, 21 %), lung cancer (64, 52 %), colorectal cancer (40, 24 %), melanoma (38, 30 %) and the haematopoietic system (37, 35 %) and for males in prostate cancer (105, 25 %), colorectal cancer (91, 45 %), the haematopoietic system (71, 55 %), bladder cancer (69, 100 %) and melanoma (64, 52 %).

Conclusions

The increase in the number of incident cancer cases of 15 % in females and 21 % in males in the next decade is very relevant for planning purposes. However, external factors cause uncertainty in the prediction of some cancer sites (mainly prostate cancer and colorectal cancer) and the prediction intervals are still broad. Therefore, our predictions must be interpreted with some caution.
Literatur
1.
Zurück zum Zitat Moller H, Fairley L, Coupland V, Okello C, Green M, Forman D, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007 May 7;96(9):1484–8. Moller H, Fairley L, Coupland V, Okello C, Green M, Forman D, et al. The future burden of cancer in England: incidence and numbers of new patients in 2020. Br J Cancer. 2007 May 7;96(9):1484–8.
2.
Zurück zum Zitat Curado MP, Edwards B, Shin H, Ferlay J, Heanue M, Boyle P, et al., editors. Cancer incidence in five continents. Volume IX. Lyon: IARC Sci Publ; 2008. Curado MP, Edwards B, Shin H, Ferlay J, Heanue M, Boyle P, et al., editors. Cancer incidence in five continents. Volume IX. Lyon: IARC Sci Publ; 2008.
3.
Zurück zum Zitat Oberaigner W, Siebert U. Are survival rates for Tyrol published in the Eurocare studies biased? Acta Oncol. 2009;48(7):984–84.PubMedCrossRef Oberaigner W, Siebert U. Are survival rates for Tyrol published in the Eurocare studies biased? Acta Oncol. 2009;48(7):984–84.PubMedCrossRef
4.
Zurück zum Zitat Dyba T, Hakulinen T, Paivarinta L. A simple non-linear model in incidence prediction. Stat Med. [Research Support, Non-U.S. Gov’t]. 1997 Oct 30;16(20):2297–309.PubMedCrossRef Dyba T, Hakulinen T, Paivarinta L. A simple non-linear model in incidence prediction. Stat Med. [Research Support, Non-U.S. Gov’t]. 1997 Oct 30;16(20):2297–309.PubMedCrossRef
5.
Zurück zum Zitat Dyba T, Hakulinen T. Do cancer predictions work? Eur J Cancer. [Research Support, Non-U.S. Gov’t]. 2008 Feb;44(3):448–53.PubMedCrossRef Dyba T, Hakulinen T. Do cancer predictions work? Eur J Cancer. [Research Support, Non-U.S. Gov’t]. 2008 Feb;44(3):448–53.PubMedCrossRef
6.
Zurück zum Zitat Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed observations. Stat Med. [Research Support, Non-U.S. Gov’t]. 1994 Aug 15;13(15):1513–23.PubMedCrossRef Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed observations. Stat Med. [Research Support, Non-U.S. Gov’t]. 1994 Aug 15;13(15):1513–23.PubMedCrossRef
7.
Zurück zum Zitat Stata Statistical Software: Release 11. College Station, Tx: StataCorp LP.2009. Stata Statistical Software: Release 11. College Station, Tx: StataCorp LP.2009.
8.
Zurück zum Zitat Dyba T, Hakulinen T. Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat Med. [Comparative Study Research Support, Non-U.S. Gov’t Validation Studies]. 2000 Jul 15;19(13):1741–52.PubMedCrossRef Dyba T, Hakulinen T. Comparison of different approaches to incidence prediction based on simple interpolation techniques. Stat Med. [Comparative Study Research Support, Non-U.S. Gov’t Validation Studies]. 2000 Jul 15;19(13):1741–52.PubMedCrossRef
9.
Zurück zum Zitat Mikulasek A. Demographisches Jahrbuch 2011. Wien: Statistik Austria; 2012. Mikulasek A. Demographisches Jahrbuch 2011. Wien: Statistik Austria; 2012.
10.
Zurück zum Zitat Bray F, Moller B. Predicting the future burden of cancer. NatRevCancer. 2006;6(1):63–74. Bray F, Moller B. Predicting the future burden of cancer. NatRevCancer. 2006;6(1):63–74.
11.
Zurück zum Zitat Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009 Jun 10;27(17):2758–65.PubMedCrossRef Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009 Jun 10;27(17):2758–65.PubMedCrossRef
12.
Zurück zum Zitat Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int. [Research Support, Non-U.S. Gov’t]. 2008 Nov;28(9):1272–9.PubMedCrossRef Pocobelli G, Cook LS, Brant R, Lee SS. Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int. [Research Support, Non-U.S. Gov’t]. 2008 Nov;28(9):1272–9.PubMedCrossRef
13.
Zurück zum Zitat Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790–801.PubMedCrossRef Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790–801.PubMedCrossRef
14.
Zurück zum Zitat Lindemann K, Eskild A, Vatten LJ, Bray F. Endometrial cancer incidence trends in Norway during 1953–2007 and predictions for 2008–2027. Int J Cancer. [Comparative Study]. 2010 Dec 1;127(11):2661–8.PubMedCrossRef Lindemann K, Eskild A, Vatten LJ, Bray F. Endometrial cancer incidence trends in Norway during 1953–2007 and predictions for 2008–2027. Int J Cancer. [Comparative Study]. 2010 Dec 1;127(11):2661–8.PubMedCrossRef
15.
Zurück zum Zitat Amiri M, Janssen F, Kunst AE. The decline in stomach cancer mortality: exploration of future trends in seven European countries. Eur J Epidemiol. 2011 Jan;26(1):23–8.PubMedCentralPubMedCrossRef Amiri M, Janssen F, Kunst AE. The decline in stomach cancer mortality: exploration of future trends in seven European countries. Eur J Epidemiol. 2011 Jan;26(1):23–8.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int. 2011 Dec;108(11):1734–8.PubMedCrossRef Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int. 2011 Dec;108(11):1734–8.PubMedCrossRef
17.
Zurück zum Zitat Coupland VH, Okello C, Davies EA, Bray F, Moller H. The future burden of cancer in London compared with England. J Public Health (Oxf). [Comparative Study]. 2010 Mar;32(1):83–9.CrossRef Coupland VH, Okello C, Davies EA, Bray F, Moller H. The future burden of cancer in London compared with England. J Public Health (Oxf). [Comparative Study]. 2010 Mar;32(1):83–9.CrossRef
18.
Zurück zum Zitat Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.]. 2005 Nov 19;366(9499):1784–93.PubMedCrossRef Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. [Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.]. 2005 Nov 19;366(9499):1784–93.PubMedCrossRef
19.
Zurück zum Zitat Strong K, Mathers C, Epping-Jordan J, Resnikoff S, Ullrich A. Preventing cancer through tobacco and infection control: how many lives can we save in the next 10 years? Eur J Cancer Prev. 2008 Apr;17(2):153–61.PubMedCrossRef Strong K, Mathers C, Epping-Jordan J, Resnikoff S, Ullrich A. Preventing cancer through tobacco and infection control: how many lives can we save in the next 10 years? Eur J Cancer Prev. 2008 Apr;17(2):153–61.PubMedCrossRef
20.
Zurück zum Zitat Soerjomataram I, Barendregt JJ, Gartner C, Kunst A, Moller H, Avendano M. Reducing inequalities in lung cancer incidence through smoking policies. Lung Cancer. [Research Support, Non-U.S. Gov’t]. 2011 Sep;73(3):268–73.PubMedCrossRef Soerjomataram I, Barendregt JJ, Gartner C, Kunst A, Moller H, Avendano M. Reducing inequalities in lung cancer incidence through smoking policies. Lung Cancer. [Research Support, Non-U.S. Gov’t]. 2011 Sep;73(3):268–73.PubMedCrossRef
21.
Zurück zum Zitat Menvielle G, Soerjomataram I, de Vries E, Engholm G, Barendregt JJ, Coebergh JW, et al. Scenarios of future lung cancer incidence by educational level: modelling study in Denmark. Eur J Cancer. [Research Support, Non-U.S. Gov’t]. 2010 Sep;46(14):2625–32.PubMedCrossRef Menvielle G, Soerjomataram I, de Vries E, Engholm G, Barendregt JJ, Coebergh JW, et al. Scenarios of future lung cancer incidence by educational level: modelling study in Denmark. Eur J Cancer. [Research Support, Non-U.S. Gov’t]. 2010 Sep;46(14):2625–32.PubMedCrossRef
22.
Zurück zum Zitat Didkowska J, Wojciechowska U, Koskinen HL, Tavilla A, Dyba T, Hakulinen T. Future lung cancer incidence in Poland and Finland based on forecasts on hypothetical changes in smoking habits. Acta Oncol. [Research Support, Non-U.S. Gov’t]. 2011 Jan;50(1):81–7.PubMedCrossRef Didkowska J, Wojciechowska U, Koskinen HL, Tavilla A, Dyba T, Hakulinen T. Future lung cancer incidence in Poland and Finland based on forecasts on hypothetical changes in smoking habits. Acta Oncol. [Research Support, Non-U.S. Gov’t]. 2011 Jan;50(1):81–7.PubMedCrossRef
23.
Zurück zum Zitat Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164(4):376–84.PubMedCrossRef Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol. 2006;164(4):376–84.PubMedCrossRef
24.
Zurück zum Zitat Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health. 2012 Feb;57(1):57–62.PubMedCentralPubMedCrossRef Oberaigner W, Siebert U, Horninger W, Klocker H, Bektic J, Schafer G, et al. Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008. Int J Public Health. 2012 Feb;57(1):57–62.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008 Apr;101(7):809–16.PubMedCrossRef Bartsch G, Horninger W, Klocker H, Pelzer A, Bektic J, Oberaigner W, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008 Apr;101(7):809–16.PubMedCrossRef
Metadaten
Titel
Prediction of cancer incidence in Tyrol/Austria for year of diagnosis 2020
verfasst von
Doz. Dr. Willi Oberaigner
Dr. Sabine Geiger-Gritsch
Publikationsdatum
01.10.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2014
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-014-0596-3

Weitere Artikel der Ausgabe 19-20/2014

Wiener klinische Wochenschrift 19-20/2014 Zur Ausgabe

MUW researcher of the month

Researcher of the Month

mitteilungen der gesellschaft

ÖGIM Flip